The CR3022 antibody was originally identified from a convalescent plasma of SARS patient and is a neutralizing antibody that binds S-RBD of SARS-CoV and SARS-CoV-2 (31, 45) without interfering with spike binding with ACE2 (31). The gene discussed is ACE2; the disease is severe acute respiratory syndrome.